New hope for castleman patients Who've run out of options
NCT ID NCT07085039
Summary
This study is testing whether the drug ruxolitinib can help adults with a rare immune system disorder called idiopathic multicentric Castleman disease (iMCD) when standard treatments have failed. Researchers will enroll 14 participants to see if the drug improves symptoms like fatigue, fever, and swollen lymph nodes while monitoring safety. The goal is to find a new treatment option for patients who currently have no established therapies after first-line treatments don't work.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTLEMAN'S DISEASE (CD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.